Please ensure Javascript is enabled for purposes of website accessibility

Vir Biotechnology and WuXi Biologics to Collaborate on COVID-19 Treatment

By Taylor Carmichael - Updated Feb 27, 2020 at 2:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

News that the two biotechs are working together on monoclonal antibody treatments for the coronavirus has excited investors.

Vir Biotechnology (VIR 2.69%) is one of several biotech companies pushing rapidly to develop potential treatments for COVID-19, a viral illness that is threatening to become a worldwide pandemic. Just two weeks ago, the company announced that its researchers had identified two monoclonal antibodies (mAbs) that might work on the coronavirus. Then on Tuesday, the company announced a new collaboration with a biotech based in Shanghai, WuXi Biologics, to develop them as therapies. WuXi will work on cell-line development, drug formulation and initial manufacturing for clinical trials.  

Under the deal, WuXi will have the rights to commercialize the COVID-19 antibodies in mainland China, while Vir will retain the rights in the rest of the world. Vir has not announced yet when clinical trials of the therapies in humans will start. "We are acutely aware of the importance of moving rapidly in response to COVID-19," said CEO George A. Scangos. "In the event that we are in a position to develop an antibody therapy, our agreement with WuXi Biologics enables us to accelerate advancement against this global threat." 

3-D rendering of Covid-19

Image source: Getty Images

Vir's stock is up 345% in 2020

So far in 2020, the biotech companies that are fighting the COVID-19 outbreak have been big winners in the stock market. Vir's market cap has more than quadrupled since the beginning of the year.  

Other big winners include Novavax, up 141%, Inovio Pharmaceuticals, up 34%, and Moderna, up 32%.  The largest gainer, however, has been a former micro-cap, Co-Diagnostics, up a startling 1,438% in 2020. That company, now valued at $243 million, recently received European Union approval for its COVID-19 diagnostic test.

Vir was up by more than 60% in mid-afternoon trading on Thursday.

Taylor Carmichael owns shares of Novavax. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
VIR
$28.60 (2.69%) $0.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.